Annual meeting explores how to overcome the challenges with patient care that community oncology practices face on a daily basis.
Oncology
Advertisement
Top news of the week from Specialty Pharmacy Times.
Advertisement
Pembrolizumab (Keytruda) met its primary endpoint in the pivotal phase 3 KEYNOTE-042 trial.
Most of the survey respondents were unaware of oncology drug shortages but would want to be told about any therapy substitutions caused by short supply.
Some studies have suggested that patients with HIV have not only a higher risk of lung cancer, but also an increased risk of mortality from lung cancer than patients without HIV.
The findings could lead to broader access to cancer drug Z-endoxifen for further clinical study
Advertisement
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Ramucirumab improved overall survival and progression-free survival in patients with advanced hepatocellular carcinoma who have a high alpha-fetoprotein.
Top news of the week from Specialty Pharmacy Times.
Advertisement
The EGFR/TNF inhibitor treatment effectively blocks the tumor necrosis factor escape route for non-small cell lung cancer.
At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Julianne Orr, PharmD, from the Indiana University Health Simon Cancer Center, discusses how pharmacists can help patients who are transitioning from an infusion product to an oral chemotherapy.
US report indicates new drivers of death have emerged over time and have continued to unequally affect residents at the state level.
The therapy is a combination of a checkpoint drug, nivolumab, and a new immune stimulation drug, ALT-803.
New drug shows promising signs of delaying the development of existing breast and lung cancers. .
Pediatric patients treated with larotrectinib in a clinical trial demonstrated a 93% response rate.
A novel chimera targets the growth factors responsible for certain types of breast cancer.
Alcohol-dependent patients with hepatitis C virus comorbidity found to have greater deficits in the frontal, precentral, superior, and orbital volumes.
According to the study, patients who take a reduced dose of abiraterone with a low-fat meal may cut costs by as much as $300,000.
Triple-negative and HER2-positive breast cancers may be unlikely to develop lymph node metastases.
Over the years, a number of landmark clinical studies on the management of breast cancer have been published, sharpening how patients are treated today.
Overweight patients with BRCA mutations may be more likely to develop breast cancer.
Top news of the week from Specialty Pharmacy Times.
Over the years, a number of landmark clinical studies on the management of breast cancer have been published, sharping how patients are treated today.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Breast cancer treatments may affect men differently than women.
Breast cancer survivors and insurance companies could gain a better understanding of mortality risk with a new model.
Chronic infection with hepatitis C virus is the leading cause of hepatocellular carcinoma.
Fuel source of cancer cells could impact their efficacy of CAR-T cell therapies for pediatric patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
2
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
3
Afamitresgene autoleucel: The First T-Cell Receptor Therapy on the Market
4
The Return of Belantamab Mafodotin: Past Lessons, Present Promise, and Future Impact
5
